Page 3 - Les meilleurs doctors traitant la maladie suivante : Cancer de la langue - TOP -77 des médecins

Le professeur Kyzas dirige l'essai MANTRA, le plus grand essai contrôlé randomisé en stomatologie et chirurgie maxillo-faciale, et se spécialise dans les traitements avancés du cancer de la langue.

• Publier plus de 70 articles scientifiques dans des revues à fort impact
• Être pionnier dans la planification personnalisée par impression 3D en chirurgie reconstructive
• Être chirurgien microvasculaire certifié avec une vaste expérience en chirurgie de la tête et du cou
• Assurer la direction clinique des services d'oncologie couvrant plus d'un million de personnes
• Être rédacteur en chef du British Journal of Oral and Maxillofacial Surgery

Le Pr Assoc. Nail Paksoy est spécialisé en oncologie médicale à l'hôpital Medipol Bahçelievler, avec une expertise dans le traitement du cancer de la langue.

• Certifié par l'ESMO en oncologie médicale
• Participer à de multiples essais cliniques internationaux pour les traitements du cancer
• Publier des recherches sur divers sujets oncologiques, y compris l'efficacité des traitements
• Formation spécialisée à l'Institut d'oncologie de l'Université d'Istanbul

Le Dr Alemdar est spécialisé en oncologie médicale, avec un accent particulier sur le cancer de la langue, grâce à une formation approfondie à l'Université Akdeniz.

• Certifié en oncologie médicale depuis 2018
• Plus de 15 ans d'expérience en oncologie et en médecine interne
• Exerce au complexe hospitalier Medical Park Antalya

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Le Dr Inta Jaunalksne est spécialisée en virothérapie – une approche immunologique de pointe pour le traitement du cancer de la langue. Forte de plus de 30 ans d'expérience, elle dirige le centre d'immunologie clinique de l'hôpital universitaire clinique Pauls Stradins.

• Se spécialiser en virothérapie pour le traitement du cancer
• Diriger le centre d'immunologie clinique d'un grand hôpital universitaire
• Être diplômée de l'Institut médical de Riga avec un internat en médecine interne

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Dr. Mohamed Mahmoud Abdelhakim is Head of Radiation Oncology at Shefa al Orman Hospital, Luxor. He is Professor of Radiation Oncology at the National Cancer Institute, Cairo University. He previously served as Associate Professor (2015–2020), Lecturer (2010–2015), Assistant Lecturer (2003–2009), and Resident (2000–2003). He also worked as a Specialist at Gharbia Cancer Society.

He treats inpatients and outpatients with breast, soft tissue sarcoma, lymphoma, gynecologic, gastrointestinal, genitourinary, and CNS tumors. His skills include image-guided brachytherapy, IMRT, VMAT, SRS, and SBRT. He performs conventional and CT-based planning and 3D-CRT. He works with cobalt and linear accelerators and electron beam therapy. He provides HDR and LDR intracavitary and interstitial brachytherapy. He also performs stereotactic radiotherapy, total body irradiation, and total skin irradiation.

Member: Egyptian Cancer Society, ESTRO, ESMO.

Le Dr Erkan Karatas est hautement qualifié en oto-rhino-laryngologie et en chirurgie de la tête et du cou, avec une vaste expérience internationale dans des institutions prestigieuses.

• Se spécialiser en chirurgie de la tête et du cou dans plusieurs centres de premier plan en Europe et aux États-Unis
• Se former à la faculté de médecine de Hanovre et dans d'autres institutions de premier plan
• Être membre de plusieurs associations internationales d'oto-rhino-laryngologie et de chirurgie de la tête et du cou

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Le Dr Topcu a été formé dans des centres d'oncologie prestigieux tels que MD Anderson et Sunnybrook Odette, se spécialisant dans les cancers de la tête et du cou, y compris le cancer de la langue.

• Internat en oncologie médicale à l'Université Technique de Karadeniz
• Membre de l'ESMO et de l'ASCO – principales sociétés mondiales d'oncologie
• Traiter un large éventail de cancers, avec une spécialisation dans les cas complexes
• Travailler à l'Hôpital Universitaire Biruni au sein d'équipes multidisciplinaires

Spécialisé en radio-oncologie à l'Université de Marmara – le Dr Sahibov se concentre sur la planification précise du traitement du cancer de la langue.

• Formé à la Faculté de Médecine de l'Université de Marmara
• Spécialisation en radio-oncologie achevée en 2016
• Travailler à l'Hôpital Emsey avec un équipement de radiothérapie de pointe